ABRAM’S CLINICAL DRUG THERAPY RATIONALES FOR
bb bb bb bb bb
NURSING PRACTICE 13th EDITION GERALYN FRANDSEN’S
bb bb bb bb bb
TESTBANK/COMPLETE GUIDE /ALL CHAPTERS 1-61
bb bb bb bb bb
,Chapter 1: The Foundation of Pharmacology: Quality and Safety
bb bb bb bb bb bb bb bb
1. A bbpatient bbdiagnosed bbwith bbobsessive–compulsive bbdisorder bbhas bbbeen bbprescribed
bboralb
paroxetine bbhydrochloride. bbWhat bb is bbthe bbexpected bbeffect bbfor bbthis
bbprescription?
A. Curative bbeffect bbon bbsymptoms
B. Systemic bbeffect bbon bbsymptoms
C. Local bbeffect bbon bbsymptoms
D. Parenteral bbeffect bbon bbsymptoms
ACCURATE bbANSWER:-B
REASONING:->>>Pharmaceutical bbdrug bbthat bbproduce bbsystemic bbeffects bbare bbtaken bbinto
bbthe bbbody, bbcirculated bbthrough bbthe bbbloodstream bbto bbtheir bbsites bbof bbaction bbin bbvarious
bbbody bbtissues, bband bbeventually bbeliminated bbfrom bbthe bbbody. bbCurative bbagents bbare bbgiven
bbto bbcure bba bbdisease bbprocess. bbInbthis bbcase, bbparoxetine bbhydrochloride bbwill bbcontrol bbthe
bbsymptoms bbbut bbnot bbcure bbthe bbdisorder.
Pharmaceutical bbdrug bbwith bblocal bbeffects, bbsuch bbas bbsunscreen bband bblocal bbanesthetics, bbact
bbmainly bbat bbthe bbsite b of bbapplication. bbParoxetine bbhydrochloride bbis bbnot bbadministered
bbparenterally. bbParenteral bbagents bare bbadministered bbsubcutaneously, bb intramuscularly, bbor
bbintravenously.
POINTS: 1 REFERENCE: p. bb3, bbIntroduction OBJ: 1
NAT: bbHospital bbclient bbNeeds: bbPhysiological bbIntegrity: bbPharmacological bband
bbParenteral bbTherapiesbTOP: Chapter: bb1: bbThe bbFoundation bbof bbPharmacology:
bbQuality bband bbSafety
KEY: b b Integrated bbProcess: bbNursing bbProcess
BLM: b b Cognitive bbLevel: bbUnderstand NOT: b b Multiple bbChoice
2. A bbhospital bbclient bbhas bbbeen bbprescribed bban bbantibiotic. bbThis bbpharmaceutical
bbdrug bbis bba bbnaturally bboccurring bsubstance bbthat bbhas bbbeen
GRADESBOOST.CO M
bbchemically modified. What bb bb i bbs bb bbanother bbname bbfor bbthis bbtype bbof bbpharmaceutical
bbdrug?
A. Synthetic bbdrug
B. Semisynthetic bbdrug
C. Biotechnology bbdrug
D. Prototype bbdrug
ACCURATE bbANSWER:-B
REASONING:->>>Semisynthetic bbpharmaceutical bbdrug bb(e.g., bbmany bbantibiotics) bbare
bbnaturally bboccurring bbsubstances bbthat bbhave bbbeen bbchemically bbmodified. bbSynthetic
bbpharmaceutical bbdrug bbare bbmore bbstandardized bbin bbtheir bbchemical bbcharacteristics, bbmore
bbconsistent bbin bbtheir bbeffects, bband bbless bblikely bbto bbproduce bballergic bbreactions.
bbBiotechnology bbpharmaceutical bbdrug bbinvolve bbmanipulating bbDNAband bbRNA bband
bbrecombining bbgenes bbinto bbhybrid bbmolecules bbthat bbcan bbbe bbinserted bbinto bbliving
bborganisms. bbPrototype bb pharmaceutical bbdrug bbare bbthe bbfirst bbdrug bbof bba bbparticular bbgroup
bbto bbbe bbdeveloped.
POINTS: 1 REFERENCE: p. bb3, bbDrug bbSources OBJ: 1
NAT: bbHospital bbclient bbNeeds: bbPhysiological bbIntegrity: bbPharmacological bband
bbParenteral bbTherapiesbTOP: Chapter: bb1: bbThe bbFoundation bbof bbPharmacology:
bbQuality bband bbSafety
KEY: b b Integrated bbProcess: bbNursing bbProcess
BLM: b b Cognitive bbLevel: bbUnderstand NOT: b b Multiple bbChoice
3. Which bbclassification bbapplies bbto bbmorphine?
A. Central bbnervous bbsystem bbdepressant
B. Central bbnervous bbsystem bbstimulant
, C. Anti-inflammatory
D. Antihypertensive
ACCURATE bbANSWER:-A
REASONING:->>>Pharmaceutical bbdrug bbare bbclassified bbaccording bbto bbtheir bbeffects bbon
bbparticular bbbody bbsystems, bbtheir bbtherapeutic bbuses, bband bbtheir bbchemical bbcharacteristics.
bbMorphine bbis bbclassified bbas bba bbcentral bbnervous bbsystem bbdepressant bband bbwill bbproduce bbthis
bbeffect bbin bbthe bbhospital bbclient. bbAbcentral bbnervous bbsystem bbstimulant bbincreases bbattention
bband bbraises bbmood. bbAn bbanti-inflammatorybagent bbdecreases bbinflammation bbat bbthe bbsite bbof
bbtissue bbor bbjoint bbinflammation. bbAn bbantihypertensivebagent bb reduces bbblood bbpressure.
POINTS: 1 REFERENCE: p. bb3, bbDrug
bbClassifications bband bbPrototypesbOBJ: 1
NAT: bbHospital bbclient bbNeeds: bbPhysiological bbIntegrity: bbPharmacological bband
bbParenteral bbTherapiesb TOP: Chapter: bb1: bbThe bbFoundation bbof bbPharmacology:
bbQuality bband bbSafety
KEY: b b Integrated bbProcess: bbNursing bbProcess
BLM: b b Cognitive bbLevel: bbRemember NOT: b b Multiple bbChoice
4. A bbhospital bbclient bbis bbadministered bbamoxicillin. bbThe bbgeneric bbname bbof bbthis
bbpharmaceutical bbdrug bbbelongs bbto bbwhichbdrug bbgroup?
A. Selective bbserotonin bbreuptake bbinhibitors
B. Diuretics
C. Penicillins
D. ACE bbinhibitors
ACCURATE bbANSWER:-C
REASONING:->>>The bbgeneric bbname bboften bbindicates bbthe bbdrug bbgroup bb(e.g., bbpharmaceutical
bbdrug
GRADESBOOST.CO
with bbgeneric bbnames bbending bbin bb―cillin‖ bbare bbpenicillins). bbSelective bbserotonin
bbreuptakebinhibitors bbare bbpharmaceutical bbdrugs
that bbhave bbantidepressant bbeffects; bbSSRI bbis bba bbbroad bbclassification, bbnot bba bbgeneric bbname.
bbDiureticsbare bbpharmaceutical bbdrugs bbthat bbincrease bburine bboutput; bbdiuretic bbis bba bbbroad
bbclassification, bbnot bba bbgeneric bbname. bbACE bbinhibitor bbis bbthe bbbroad bbclassification bbfor bbthe
bbangiotensin bbreceptor bbblockers, bbnot bbthebgeneric bb name.
POINTS: 1 REFERENCE: p. bb3, bbDrug bbNames OBJ: 2
NAT: bbHospital bbclient bbNeeds: bbPhysiological bbIntegrity: bbPharmacological bband
bbParenteral bbTherapiesbTOP: Chapter: bb1: bbThe bbFoundation bbof bbPharmacology:
bbQuality bband bbSafety
KEY: b b Integrated bbProcess: bbNursing bbProcess
BLM: b b Cognitive bbLevel: bbUnderstand NOT: b b Multiple bbChoice
5. The bbadministration bbof bbdiphenhydramine bbis bbregulated bbbybbwhich bbU.S. bbgovernment bbagency?
A. Public bbHealth bbService
B. Federal bbTrade bbCommission
C. Occupational bbSafety bband bbHealth bbAdministration
D. Food bband
DrugbAdministrati
bb
on
ACCURATE bbANSWER:-D
, REASONING:->>>The bbFood bband bbDrug bbAdministration bbapproves bbpharmaceutical
bbdrug bbfor bbover- bbthe-counter bbavailability, bbincluding bbthe bbtransfer bbof bbpharmaceutical
bbdrug bbfrom bbprescription bbto bbOTC bbstatus, bband bbmay bbrequire bbclinical bbtrials bbto bbdetermine
bbthe bbsafety bband bbeffectiveness bbof bbOTC bbuse.bThe bbPublic bbHealth bbService bbis bbregulated bbby
bbthe bbstate bbto bbmaintain bbthe bbhealth bbof bbindividual bbcitizens bbof bbthe bbstate. bbThe bbFederal
bbTrade bbCommission bbregulates bbimports bband bbexports bbthroughout bbthe bbnation. bbThe
bbOccupational bbSafety bband bbHealth bbAdministration bbregulates bbsafetybwithin bbthe bbworkplace.
POINTS: 1 REFERENCE: p. bb4, bbPrescription bband bbNonprescription
Pharmaceutical bbdrug bbOBJ: 4
NAT: bbHospital bbclient bbNeeds: bbPhysiological bbIntegrity: bbPharmacological bband
bbParenteral bbTherapiesbTOP: Chapter: bb1: bbThe bbFoundation bbof bbPharmacology:
bbQuality bband bbSafety
KEY: b b Integrated bbProcess: bbNursing bbProcess
BLM: b b Cognitive bbLevel: bbUnderstand NOT: b b Multiple bbChoice
6. In bbthe bbU.S., bbthe bbadministration bbof bbanabolic bbsteroids bbis bbregulated bbbybbwhich bblaw?
A. The bbFood, bbDrug, bband bbCosmetic bbAct bbof bb1938
B. The bbComprehensive bbDrug bbAbuse bbPrevention bband bbControl bbAct
C. The bbHarrison bbNarcotic bbAct
D. The bbSherley bbAmendment
ACCURATE bbANSWER:-B
REASONING:->>>The bbComprehensive bbDrug bbAbuse bbPrevention bband bbControl bbAct
bbregulates bbthe bbmanufacture bband bbdistribution bbof bbnarcotics, bbstimulants, bbdepressants,
bbhallucinogens, bband bbanabolic bbsteroids. bbThe bbFood, bbDrug, bband bbCosmetic bbAct bbof bb1938
bbrevised bband bbbroadened bbFDA bbpowers bband bbresponsibilities, bbgiving bbthe bbFDA bbcontrol
bbover bbdrug bbsafety. bbThe bbHarrison bbNarcotic bbAct bbrestricted bbthe bbimportation, bbmanufacture,
bbsale, bband bbuse bbof bbopium,b cocaine, bbmarijuana, bband bbother bbpharmaceuticalbbdrugbbthat bbthe bbact bbd
bbe bbfbbi G
nbbeRd AaDs b b E
naSrcBoO
tiO
csS Th.eCSOhM
. bbT erley bbAmendment bbofbb1912 bbprohibited bbfraudulent bbclaims
bbof bbdrug bbeffectiveness.
POINTS: 1 REFERENCE: p. bb4, bbPrescription bband bbNonprescription
Pharmaceutical bbdrug bbOBJ: 3
NAT: bbHospital bbclient bbNeeds: bbPhysiological bbIntegrity: bbPharmacological bband
bbParenteral bbTherapiesbTOP: Chapter: bb1: bbThe bbFoundation bbof bbPharmacology:
bbQuality bband bbSafety
KEY: b b Integrated bbProcess: bbNursing bbProcess
BLM: b b Cognitive bbLevel: bbRemember NOT: b b Multiple bbChoice
7. A bbnursing bbattendant bbis bbresponsible bbfor bbmaintaining bban bbaccurate bbcount bband bbrecord
bbof bbthe bbcontrolled bbsubstances bbon bbthe bbnursing bbdivision. bbThis bbnursing bbaction bbis
bbregulated bbby bbwhich
U.S. bblaw bbor bbagency?
A. The bbFood, bbDrug, bband bbCosmetic bbAct bbof bb1938
B. The bbPublic bbHealth bbService
C. The bbDrug bbEnforcement b b Administration
D. ThebbSherley
AmendmentbACCURATE
bb
bb ANSWER:-C
bb bb bb bb bb
NURSING PRACTICE 13th EDITION GERALYN FRANDSEN’S
bb bb bb bb bb
TESTBANK/COMPLETE GUIDE /ALL CHAPTERS 1-61
bb bb bb bb bb
,Chapter 1: The Foundation of Pharmacology: Quality and Safety
bb bb bb bb bb bb bb bb
1. A bbpatient bbdiagnosed bbwith bbobsessive–compulsive bbdisorder bbhas bbbeen bbprescribed
bboralb
paroxetine bbhydrochloride. bbWhat bb is bbthe bbexpected bbeffect bbfor bbthis
bbprescription?
A. Curative bbeffect bbon bbsymptoms
B. Systemic bbeffect bbon bbsymptoms
C. Local bbeffect bbon bbsymptoms
D. Parenteral bbeffect bbon bbsymptoms
ACCURATE bbANSWER:-B
REASONING:->>>Pharmaceutical bbdrug bbthat bbproduce bbsystemic bbeffects bbare bbtaken bbinto
bbthe bbbody, bbcirculated bbthrough bbthe bbbloodstream bbto bbtheir bbsites bbof bbaction bbin bbvarious
bbbody bbtissues, bband bbeventually bbeliminated bbfrom bbthe bbbody. bbCurative bbagents bbare bbgiven
bbto bbcure bba bbdisease bbprocess. bbInbthis bbcase, bbparoxetine bbhydrochloride bbwill bbcontrol bbthe
bbsymptoms bbbut bbnot bbcure bbthe bbdisorder.
Pharmaceutical bbdrug bbwith bblocal bbeffects, bbsuch bbas bbsunscreen bband bblocal bbanesthetics, bbact
bbmainly bbat bbthe bbsite b of bbapplication. bbParoxetine bbhydrochloride bbis bbnot bbadministered
bbparenterally. bbParenteral bbagents bare bbadministered bbsubcutaneously, bb intramuscularly, bbor
bbintravenously.
POINTS: 1 REFERENCE: p. bb3, bbIntroduction OBJ: 1
NAT: bbHospital bbclient bbNeeds: bbPhysiological bbIntegrity: bbPharmacological bband
bbParenteral bbTherapiesbTOP: Chapter: bb1: bbThe bbFoundation bbof bbPharmacology:
bbQuality bband bbSafety
KEY: b b Integrated bbProcess: bbNursing bbProcess
BLM: b b Cognitive bbLevel: bbUnderstand NOT: b b Multiple bbChoice
2. A bbhospital bbclient bbhas bbbeen bbprescribed bban bbantibiotic. bbThis bbpharmaceutical
bbdrug bbis bba bbnaturally bboccurring bsubstance bbthat bbhas bbbeen
GRADESBOOST.CO M
bbchemically modified. What bb bb i bbs bb bbanother bbname bbfor bbthis bbtype bbof bbpharmaceutical
bbdrug?
A. Synthetic bbdrug
B. Semisynthetic bbdrug
C. Biotechnology bbdrug
D. Prototype bbdrug
ACCURATE bbANSWER:-B
REASONING:->>>Semisynthetic bbpharmaceutical bbdrug bb(e.g., bbmany bbantibiotics) bbare
bbnaturally bboccurring bbsubstances bbthat bbhave bbbeen bbchemically bbmodified. bbSynthetic
bbpharmaceutical bbdrug bbare bbmore bbstandardized bbin bbtheir bbchemical bbcharacteristics, bbmore
bbconsistent bbin bbtheir bbeffects, bband bbless bblikely bbto bbproduce bballergic bbreactions.
bbBiotechnology bbpharmaceutical bbdrug bbinvolve bbmanipulating bbDNAband bbRNA bband
bbrecombining bbgenes bbinto bbhybrid bbmolecules bbthat bbcan bbbe bbinserted bbinto bbliving
bborganisms. bbPrototype bb pharmaceutical bbdrug bbare bbthe bbfirst bbdrug bbof bba bbparticular bbgroup
bbto bbbe bbdeveloped.
POINTS: 1 REFERENCE: p. bb3, bbDrug bbSources OBJ: 1
NAT: bbHospital bbclient bbNeeds: bbPhysiological bbIntegrity: bbPharmacological bband
bbParenteral bbTherapiesbTOP: Chapter: bb1: bbThe bbFoundation bbof bbPharmacology:
bbQuality bband bbSafety
KEY: b b Integrated bbProcess: bbNursing bbProcess
BLM: b b Cognitive bbLevel: bbUnderstand NOT: b b Multiple bbChoice
3. Which bbclassification bbapplies bbto bbmorphine?
A. Central bbnervous bbsystem bbdepressant
B. Central bbnervous bbsystem bbstimulant
, C. Anti-inflammatory
D. Antihypertensive
ACCURATE bbANSWER:-A
REASONING:->>>Pharmaceutical bbdrug bbare bbclassified bbaccording bbto bbtheir bbeffects bbon
bbparticular bbbody bbsystems, bbtheir bbtherapeutic bbuses, bband bbtheir bbchemical bbcharacteristics.
bbMorphine bbis bbclassified bbas bba bbcentral bbnervous bbsystem bbdepressant bband bbwill bbproduce bbthis
bbeffect bbin bbthe bbhospital bbclient. bbAbcentral bbnervous bbsystem bbstimulant bbincreases bbattention
bband bbraises bbmood. bbAn bbanti-inflammatorybagent bbdecreases bbinflammation bbat bbthe bbsite bbof
bbtissue bbor bbjoint bbinflammation. bbAn bbantihypertensivebagent bb reduces bbblood bbpressure.
POINTS: 1 REFERENCE: p. bb3, bbDrug
bbClassifications bband bbPrototypesbOBJ: 1
NAT: bbHospital bbclient bbNeeds: bbPhysiological bbIntegrity: bbPharmacological bband
bbParenteral bbTherapiesb TOP: Chapter: bb1: bbThe bbFoundation bbof bbPharmacology:
bbQuality bband bbSafety
KEY: b b Integrated bbProcess: bbNursing bbProcess
BLM: b b Cognitive bbLevel: bbRemember NOT: b b Multiple bbChoice
4. A bbhospital bbclient bbis bbadministered bbamoxicillin. bbThe bbgeneric bbname bbof bbthis
bbpharmaceutical bbdrug bbbelongs bbto bbwhichbdrug bbgroup?
A. Selective bbserotonin bbreuptake bbinhibitors
B. Diuretics
C. Penicillins
D. ACE bbinhibitors
ACCURATE bbANSWER:-C
REASONING:->>>The bbgeneric bbname bboften bbindicates bbthe bbdrug bbgroup bb(e.g., bbpharmaceutical
bbdrug
GRADESBOOST.CO
with bbgeneric bbnames bbending bbin bb―cillin‖ bbare bbpenicillins). bbSelective bbserotonin
bbreuptakebinhibitors bbare bbpharmaceutical bbdrugs
that bbhave bbantidepressant bbeffects; bbSSRI bbis bba bbbroad bbclassification, bbnot bba bbgeneric bbname.
bbDiureticsbare bbpharmaceutical bbdrugs bbthat bbincrease bburine bboutput; bbdiuretic bbis bba bbbroad
bbclassification, bbnot bba bbgeneric bbname. bbACE bbinhibitor bbis bbthe bbbroad bbclassification bbfor bbthe
bbangiotensin bbreceptor bbblockers, bbnot bbthebgeneric bb name.
POINTS: 1 REFERENCE: p. bb3, bbDrug bbNames OBJ: 2
NAT: bbHospital bbclient bbNeeds: bbPhysiological bbIntegrity: bbPharmacological bband
bbParenteral bbTherapiesbTOP: Chapter: bb1: bbThe bbFoundation bbof bbPharmacology:
bbQuality bband bbSafety
KEY: b b Integrated bbProcess: bbNursing bbProcess
BLM: b b Cognitive bbLevel: bbUnderstand NOT: b b Multiple bbChoice
5. The bbadministration bbof bbdiphenhydramine bbis bbregulated bbbybbwhich bbU.S. bbgovernment bbagency?
A. Public bbHealth bbService
B. Federal bbTrade bbCommission
C. Occupational bbSafety bband bbHealth bbAdministration
D. Food bband
DrugbAdministrati
bb
on
ACCURATE bbANSWER:-D
, REASONING:->>>The bbFood bband bbDrug bbAdministration bbapproves bbpharmaceutical
bbdrug bbfor bbover- bbthe-counter bbavailability, bbincluding bbthe bbtransfer bbof bbpharmaceutical
bbdrug bbfrom bbprescription bbto bbOTC bbstatus, bband bbmay bbrequire bbclinical bbtrials bbto bbdetermine
bbthe bbsafety bband bbeffectiveness bbof bbOTC bbuse.bThe bbPublic bbHealth bbService bbis bbregulated bbby
bbthe bbstate bbto bbmaintain bbthe bbhealth bbof bbindividual bbcitizens bbof bbthe bbstate. bbThe bbFederal
bbTrade bbCommission bbregulates bbimports bband bbexports bbthroughout bbthe bbnation. bbThe
bbOccupational bbSafety bband bbHealth bbAdministration bbregulates bbsafetybwithin bbthe bbworkplace.
POINTS: 1 REFERENCE: p. bb4, bbPrescription bband bbNonprescription
Pharmaceutical bbdrug bbOBJ: 4
NAT: bbHospital bbclient bbNeeds: bbPhysiological bbIntegrity: bbPharmacological bband
bbParenteral bbTherapiesbTOP: Chapter: bb1: bbThe bbFoundation bbof bbPharmacology:
bbQuality bband bbSafety
KEY: b b Integrated bbProcess: bbNursing bbProcess
BLM: b b Cognitive bbLevel: bbUnderstand NOT: b b Multiple bbChoice
6. In bbthe bbU.S., bbthe bbadministration bbof bbanabolic bbsteroids bbis bbregulated bbbybbwhich bblaw?
A. The bbFood, bbDrug, bband bbCosmetic bbAct bbof bb1938
B. The bbComprehensive bbDrug bbAbuse bbPrevention bband bbControl bbAct
C. The bbHarrison bbNarcotic bbAct
D. The bbSherley bbAmendment
ACCURATE bbANSWER:-B
REASONING:->>>The bbComprehensive bbDrug bbAbuse bbPrevention bband bbControl bbAct
bbregulates bbthe bbmanufacture bband bbdistribution bbof bbnarcotics, bbstimulants, bbdepressants,
bbhallucinogens, bband bbanabolic bbsteroids. bbThe bbFood, bbDrug, bband bbCosmetic bbAct bbof bb1938
bbrevised bband bbbroadened bbFDA bbpowers bband bbresponsibilities, bbgiving bbthe bbFDA bbcontrol
bbover bbdrug bbsafety. bbThe bbHarrison bbNarcotic bbAct bbrestricted bbthe bbimportation, bbmanufacture,
bbsale, bband bbuse bbof bbopium,b cocaine, bbmarijuana, bband bbother bbpharmaceuticalbbdrugbbthat bbthe bbact bbd
bbe bbfbbi G
nbbeRd AaDs b b E
naSrcBoO
tiO
csS Th.eCSOhM
. bbT erley bbAmendment bbofbb1912 bbprohibited bbfraudulent bbclaims
bbof bbdrug bbeffectiveness.
POINTS: 1 REFERENCE: p. bb4, bbPrescription bband bbNonprescription
Pharmaceutical bbdrug bbOBJ: 3
NAT: bbHospital bbclient bbNeeds: bbPhysiological bbIntegrity: bbPharmacological bband
bbParenteral bbTherapiesbTOP: Chapter: bb1: bbThe bbFoundation bbof bbPharmacology:
bbQuality bband bbSafety
KEY: b b Integrated bbProcess: bbNursing bbProcess
BLM: b b Cognitive bbLevel: bbRemember NOT: b b Multiple bbChoice
7. A bbnursing bbattendant bbis bbresponsible bbfor bbmaintaining bban bbaccurate bbcount bband bbrecord
bbof bbthe bbcontrolled bbsubstances bbon bbthe bbnursing bbdivision. bbThis bbnursing bbaction bbis
bbregulated bbby bbwhich
U.S. bblaw bbor bbagency?
A. The bbFood, bbDrug, bband bbCosmetic bbAct bbof bb1938
B. The bbPublic bbHealth bbService
C. The bbDrug bbEnforcement b b Administration
D. ThebbSherley
AmendmentbACCURATE
bb
bb ANSWER:-C
